NYSEAMERICAN:APHB

Ampliphi Biosciences Stock Forecast, Price & News

$4.29

-0.30 (-6.54 %)

(As of 06/14/2021 12:00 AM ET)

Add

Compare

Today's Range

$4.21

▼

$4.79

50-Day Range N/A

52-Week Range

$0.15

▼

$1.37

Volume37,547 shs

Average Volume842,200 shs

Market Capitalization$143.58 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive APHB News and Ratings via Email

Sign-up to receive the latest news and ratings for Ampliphi Biosciences and its competitors with MarketBeat's FREE daily newsletter.

About Ampliphi Biosciences

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.

Ampliphi Biosciences (NYSEAMERICAN:APHB) Trading Down 1.5%
May 29, 2021 | americanbankingnews.com

Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc.,
April 30, 2020 | www.bloomberg.com

C3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc.
May 9, 2019 | finance.yahoo.com

AmpliPhi Biosciences Announces Stockholder Approval of Business Combination with C3J Therapeutics
May 8, 2019 | finance.yahoo.com

C3J Therapeutics Announces Issuance of U.S. Patent Covering Synthetic Bacteriophage
April 2, 2019 | www.businesswire.com

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of AmpliPhi Biosciences Corporation - APHB
March 27, 2019 | finance.yahoo.com

AmpliPhi Biosciences Corporation Estimate Momentum
March 18, 2019 | www.nasdaq.com

AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)
January 15, 2019 | seekingalpha.com

AmpliPhi Biosciences and C3J Therapeutics Agree to Merge
January 4, 2019 | www.bizjournals.com

AmpliPhi Bio up 45% premarket on merger with C3J Therapeutics
January 4, 2019 | seekingalpha.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:APHB
Previous SymbolAMEX:APHB
CUSIPN/A
CIK921114
Webwww.ampliphibio.com
Phone+1-804-8272524
Employees30
Year FoundedN/A

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares33,469,000
Market Cap$143.58 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.56 out of 5 stars

Medical Sector

1506th out of 2,100 stocks

Biotechnology Industry

25th out of 88 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Ampliphi Biosciences.

2.8 Community Rank

Outperform Votes
Ampliphi Biosciences has received 205 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Ampliphi Biosciences has received 165 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Ampliphi Biosciences has received 55.41% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Ampliphi Biosciences and other stocks. Vote “Outperform” if you believe APHB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe APHB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Ampliphi Biosciences does not currently pay a dividend.
Dividend Growth
Ampliphi Biosciences does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ampliphi Biosciences insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Ampliphi Biosciences (NYSEAMERICAN:APHB) Frequently Asked Questions

What stocks does MarketBeat like better than Ampliphi Biosciences?

Wall Street analysts have given Ampliphi Biosciences a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ampliphi Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Ampliphi Biosciences' earnings last quarter?

Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) released its quarterly earnings data on Monday, March, 25th. The biotechnology company reported ($0.15) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.07.
View Ampliphi Biosciences' earnings history.

Who are Ampliphi Biosciences' key executives?

Ampliphi Biosciences' management team includes the following people:

Dr. Paul C. Grint, CEO & Director (Age 61)
Mr. Steven R. Martin, Sr. VP & CFO (Age 58)
Mr. Michael Scott Salka, Consultant (Age 57)

Who are some of Ampliphi Biosciences' key competitors?

Some companies that are related to Ampliphi Biosciences include Silence Therapeutics (SLN), Pfenex (PFNX), Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI), Theratechnologies (TH), Aptose Biosciences (APS), Burcon NutraScience (BU), BELLUS Health (BLU), ProMetic Life Sciences (PLI), Synairgen (SNG), Neptune Wellness Solutions (NEPT), Medicenna Therapeutics (MDNA), Emblem (EMC), Novacyt (NCYT), Open Orphan (ORPH) and Arix Bioscience (ARIX).
View all of APHB's competitors.

What other stocks do shareholders of Ampliphi Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ampliphi Biosciences investors own include Navios Maritime Partners (NMM), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Protalix BioTherapeutics (PLX), Synergy Pharmaceuticals (SGYP), AcelRx Pharmaceuticals (ACRX), Athersys (ATHX), Actinium Pharmaceuticals (ATNM), Anavex Life Sciences (AVXL) and Corbus Pharmaceuticals (CRBP).

What is Ampliphi Biosciences' stock symbol?

Ampliphi Biosciences trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "APHB."

How do I buy shares of Ampliphi Biosciences?

Shares of APHB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ampliphi Biosciences' stock price today?

One share of APHB stock can currently be purchased for approximately $4.29.

How much money does Ampliphi Biosciences make?

Ampliphi Biosciences has a market capitalization of $143.58 million.

How many employees does Ampliphi Biosciences have?

Ampliphi Biosciences employs 30 workers across the globe.

What is Ampliphi Biosciences' official website?

The official website for Ampliphi Biosciences is www.ampliphibio.com.

Where are Ampliphi Biosciences' headquarters?

Ampliphi Biosciences is headquartered at 3579 Valley Centre Drive, SAN DIEGO, CA 92130, United States.

How can I contact Ampliphi Biosciences?

Ampliphi Biosciences' mailing address is 3579 Valley Centre Drive, SAN DIEGO, CA 92130, United States. The biotechnology company can be reached via phone at +1-804-8272524.

This page was last updated on 6/14/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Ampliphi Biosciences Stock Forecast, Price & News

About Ampliphi Biosciences

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

Consensus Rating

2.8 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment